Based on Figures 2 and 4, using CRISPR-Cas9 can lower BCL11A expression, which in turn causes γ-haemoglobin levels to increase. In accordance with Figure 3, y-haemoglobin levels remain elevated for at least 18 months, with long-term utility being unknown. Generally, increased foetal haemoglobin production could significantly reduce the morbidity and mortality of beta-thalassemia by limiting the number of required blood transfusions and reducing complications. Insert a line graph to extrapolate the trend based on the available information for predicting the future.

Question

Based on Figures 2 and 4, using CRISPR-Cas9 can lower BCL11A expression, which in turn causes γ-haemoglobin levels to increase. In accordance with Figure 3, y-haemoglobin levels remain elevated for at least 18 months, with long-term utility being unknown. Generally, increased foetal haemoglobin production could significantly reduce the morbidity and mortality of beta-thalassemia by limiting the number of required blood transfusions and reducing complications. Insert a line graph to extrapolate the trend based on the available information for predicting the future.
is this all necssary or is there anything i have dlete answer in a sentence

GPT 3.5 · Answer

This information is all necessary for providing a comprehensive understanding of the potential benefits of using CRISPR-Cas9 to lower BCL11A expression and increase γ-haemoglobin levels in beta-thalassemia patients.